Vaxcyte surges on pneumococcal vaccine late-stage trial success

By Reuters News

** Vaxcyte shares PCVX.O jump 26% to $71.17 premarket

** Vaxcyte says its 31-strain pneumonia vaccine, VAX-31, meets all main goals in a late-stage trial and generates immune responses comparable to or better than Pfizer's PFE.N Prevnar 20 and Merck's MRK.N Capvaxive

** The vaccine is as safe and well tolerated as the current vaccines

** Vaxcyte expects results from two more late-stage trials in H1 2027 and plans to apply for FDA approval in H1 2028

** As of last close, stock up 22.4% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.